Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days
Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days